Jason Frischhertz, MD
Urology · Mobile, ALNPI 1487066411
Payments from drug & device makers
What this record shows
33 manufacturers reported payments, led by Intuitive Surgical at 43.2% of the total. Reporting peaked in 2023 at $3,426 and has fallen 88.1% since, to $409 in 2025.
Across 174 payments — averaging $39.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Astellas Pharma US Inc$753
- Johnson & Johnson$447
- Boston Scientific$360
- Pfizer$294
- Procept Biorobotics Corporation$281
- plus $2K from 27 others
Across 1 payment — averaging $7000.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Cornerstone Urology Network, LLC$7K
What the payments were for
- Food & beverage$3,55451%
- Education$3,39449%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 1 | $3,000 |
| Astellas Pharma US Inc | 33 | $753 |
| Johnson & Johnson(2 entities) | 31 | $447 |
| Boston Scientific | 4 | $360 |
| Pfizer | 17 | $294 |
| Procept Biorobotics Corporation | 4 | $281 |
| Endo Pharmaceuticals Inc. | 9 | $186 |
| Sumitomo Pharma America, Inc. | 9 | $149 |
| Urogen Pharma, Inc. | 8 | $142 |
| Urovant Sciences Inc | 7 | $125 |
| Endo USA, Inc. | 5 | $121 |
| Bayer | 2 | $115 |
| Dendreon Pharmaceuticals LLC | 4 | $111 |
| Cook Medical LLC | 1 | $97 |
| Merck | 5 | $94 |
| AbbVie(2 entities) | 5 | $84 |
| Olympus America Inc. | 1 | $71 |
| Accord Healthcare, Inc. | 3 | $70 |
| Conmed Corporation | 1 | $68 |
| Antares Pharma, Inc. | 3 | $61 |
| Novartis | 3 | $47 |
| Baxter Healthcare | 2 | $36 |
| Amgen | 2 | $32 |
| Medtronic | 1 | $29 |
| Teleflex LLC | 1 | $27 |
| Tempus AI, Inc | 1 | $25 |
| Coloplast | 2 | $24 |
| Blue Earth Diagnostics | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Halozyme Inc | 1 | $13 |
| Travere Therapeutics, Inc. | 4 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$3,000
- AQUABEAM SYSTEM$160
- REZUM$122
- AMS$121
- Nubeqa$102
- GENERAL BPH$102
How this compares
$6,948 in reported general payments places this provider in the 75th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 94 | $74,974 |
| Abiraterone Acetate | 50 | $60,255 |
| OrgovyxRelugolix | 17 | $44,412 |
| GemtesaVibegron | 14 | $13,362 |
| Tamsulosin Hcl | 375 | $4,777 |
| Tolterodine Tartrate ErTolterodine Tartrate | 18 | $2,054 |
| Oxybutynin Chloride ErOxybutynin Chloride | 110 | $1,877 |
| Finasteride | 148 | $1,521 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 47 | $1,142 |
| Methenamine Hippurate | 11 | $927 |
| Testosterone Cypionate | 29 | $868 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 26 | $347 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 68 | $342 |
| Ketorolac Tromethamine | 30 | $329 |
| Prednisone | 53 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $753 | $74,97494 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $149 | $57,77331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 179 urology providers in Alabama.
Other urology in Mobile
- Lorie FleckMobile$26K
- Zachary ReardonMobile$19K
- Ted KleinMobile$18K
- Austin YoungerMobile$18K
- William BlaylockMobile$13K
- Guy OswaltMobile$9K
- Kristie Blanchard-BurchMobile$8K
- Paul ScottMobile$8K
- William SandersonMobile$7K
- Robert HelmMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.